Skip to main content

Table 1 Summary of major trials with immunotherapy in advanced cutaneous melanoma

From: Spotlight on landmark oncology trials: the latest evidence and novel trial designs

Study N (% 1st line) ORR Median PFS 2-year OS rate
Pembrolizumab (10 mg/kg every 2 weeks)
KEYNOTE-006
Robert et al., 2015 [11]
Schachter et al., 2016 [12]
279 (65.6%) 33.7% 5.6 months 55.0%
Pembrolizumab (10 mg/kg every 3 weeks)
KEYNOTE-006 Robert et al., 2015 [11]
Schachter et al., 2016 [12]
277 (66.8%) 32.9% 4.1 months 55.0%
Nivolumab in BRAF-negative melanoma Checkmate-066 Robert et al., 2015 [13] 210 (100%) 40.0% 5.4 months 57.7%
Ipilimumab + Nivolumab Checkmate-067 Larkin et al., 2015 [14]
Larkin et al., 2017 [15]
314 (100%) 58.9% 11.7 months 64.0%
  1. ORR overall response rate; OS overall survival; PFS progression-free survival